Press Enter to search · Esc to close
Synthetic peptides now account for more than 1 in 10 new FDA-approved chemical entities. The frontier safety question isn't potency — it's what your immune system makes of the molecule, and the impurities riding alongside it.
GLP-1s rewrote metabolic medicine, but the syringe is still the weak link. New buccal devices and oral formulations are trying to close the gap — and the data is finally getting interesting.
The dual GIP/GLP-1 agonist is moving past weight loss into lipid repair and intracranial pressure relief. But a small case series flags a risk off-label users haven't been warned about.
Semaglutide and liraglutide are quietly migrating from diabetes clinics into stem-cell labs and rare-disease wards — even as a social-media-driven shortage exposes the cost of off-label demand.